Benefit of SeptiFast Multiplex PCR in the Etiologic Diagnosis and Therapeutic Approach for Onco-hematology Patients Presenting Sepsis

This study has double purpose :

• To compare the results obtained from the SeptiFast system with the results from classical microbiological sampling, in particular hemoculture, for immunosuppressed patients presenting sepsis.
• To perform a blind assessment of the benefit of septiFast care of these patients.

Inclusion criteria

All patients with onco-hematologic or cancerous pathology, or hematologic disease with chemotherapy and/or radiotherapy and/or some other immunosuppressant treatment in progress presenting an infection requiring hospitalisation and meeting the following criteria:

• Sepsis (at least one of the following signs):

• Fever > 38.2°C or hypothermia < 36°C
• FO120 min
• PA<120 mmHg (or 50 mmHg reduction in base numbers)
• Respiratory F > 30/min
• Confusion
• Hyperleucocytosis (>12 G/l) or leucopenia (<4 G/l)
• C-Reactive protein > 40
• With or without organ dysfunction as defined by :

• Hypoxia (PaO2/FiO2<300mmHg)
• Oliguria (urine deficiency<0.5 ml/kg/h in probed patient)
• Creatinine > 200umol/l
• INR>1.5 or TCA>2 X control in the absence of anticoagulant treatment
• Platelets < 100 G/l
• Bilirubin > 35 umol/l
• Lactatemia > 2 mmol/l
• Arterial hypotension (PAS<90mmHg, or PAM<70mmHg or reduction of more than 40 mmHG if known hypertension)

Exclusion criteria

• Minor patient
• Pregnancy
• A patient cannot be included again within 15 days of his/her preceding inclusion